title: Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report.
abstract: Peripheral T-cell lymphoma (PTCL) represents a small heterogeneous group of non-Hodgkin lymphoma (NHL) that accounts for ~10% of NHLs in western countries and ~25% of NHLs in Japan. The disease remains extremely difficult to treat. Therefore, novel treatment modalities are required. Mogamulizumab is a humanized immunoglobulin G1 monoclonal antibody that targets CC chemokine receptor 4. To the best of our knowledge, the efficacy of mogamulizumab in patients who are refractory to conventional chemotherapy following autologous stem cell transplantation has not been investigated previously. The present study reports a patient with PTCL who relapsed following autologous stem cell transplantation and became resistant to salvage chemotherapy, in whom mogamulizumab showed evident efficacy without severe adverse event.
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
authors.forename: Yukie
authors.initials: Y
authors.lastname: Fujita
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
authors.forename: Aya
authors.initials: A
authors.lastname: Nakaya
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
authors.forename: Shinya
authors.initials: S
authors.lastname: Fujita
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Hotta
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Yoshimura
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Azuma
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
authors.forename: Takahisa
authors.initials: T
authors.lastname: Nakanishi
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Satake
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Ishii
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
authors.forename: Tomoki
authors.initials: T
authors.lastname: Ito
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
authors.forename: Shosaku
authors.initials: S
authors.lastname: Nomura
keywords: autologous stem cell transplantation; chemokine receptor 4 antibody; mogalimuzumab; peripheral T-cell lymphoma